aMoon is a global HealthTech and Life Sciences venture capital fund based in Israel, partnering with entrepreneurs who harness groundbreaking science and technology to transform healthcare. The firm operates through aMoon Velocity (early-stage) and aMoon Growth (growth-stage) funds, investing in biopharma, medtech, and digital health companies across the US, Europe, and Israel.
40% of their portfolio is in Healthcare. Deal activity decreased year-over-year (3 deals in the last 12 months vs 7 prior). Average disclosed round size is $44.5M (across 60 rounds with reported amounts).
Portfolio
48
Fund Size
$750M
Top Stage
Series C
Last 12 Mo
3
Team
Moshic Mor, MBA
General Partner
Todd Sone, MBA
General Partner
Yaron Daniely, PhD, MBA
General Partner & Head of aMoon Alpha
Roy Wiesner, Adv., MPA
Partner
Gaby Hirsch
VP Investor Relations
Yodfat Melzer, CPA, MBA
VP Finance
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Positive Development | Unknown | $45M | Jan 2026 |
 Sera Prognostics | Series E | $100M | Jan 2026 |
 Hopscotch | Series D | $53M | Jan 2026 |
 Lin Health | Series A | $11M | Dec 2025 |
 Adcytherix | Series A | — | Oct 2025 |
| IIantrek | Series C | $42M | Aug 2025 |
 MAGENTIQ EYE | Series A | — | Jul 2025 |
| LLutris Pharma | Unknown | $30M | Jan 2025 |
| IIantrek | Series C | — | Jan 2025 |
 Character Bio | Series B | $93M | Jan 2025 |
| Lin Health | Series A | $11M | Jan 2025 |
 Lyfegen | Series A | $8M | Dec 2024 |
 MetaSight Diagnostics | Series A | $8M | Nov 2024 |
 Air Doctor | Series B | $20M | Oct 2024 |
| AAir Doctor | Series B | $20M | Oct 2024 |
| MMetaSight | Series A | $8M | Jan 2024 |
| Lyfegen | Series A | — | Jan 2024 |
 IBEX | Series C | $55M | Sep 2023 |
 Ibex Medical Analytics | Series C | $55M | Sep 2023 |
 Better Life Partners | Series B | $26.5M | Aug 2023 |
| EEleos Health | Series B | $40M | Jan 2023 |
| NNectin Therapeutics | Series A | — | Nov 2022 |
 Theranica | Series C | $45M | Aug 2022 |
 Ultima Genomics | Growth | — | May 2022 |
 Omada | Series E | $192M | Feb 2022 |
Top Co-Investors
Last updated: 20 October 2026